Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1086-1087
Number of pages2
JournalEar and Hearing
Volume43
Issue number3
DOIs
StatePublished - 8 May 2022

ASJC Scopus subject areas

  • Speech and Hearing
  • Otorhinolaryngology

Cite this